Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

RAPT Therapeutics

Explore full profile

Develops clinical-stage therapies targeting inflammatory and immunological diseases through small-molecule and biologic drug research

San Francisco, United StatesFounded 2013Biotech & Life Sciences
Valuation $1.53B Market cap · 2026
Revenue $1.5M Latest reported FY
Total funding $100–500M Disclosed equity funding

About RAPT Therapeutics

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral therapeutics aimed at targeting key drivers of the immune system. The company's mission is to transform the treatment of cancer and inflammatory diseases through cutting-edge science. RAPT Therapeutics primarily serves patients suffering from cancer and inflammatory conditions, offering them new hope through advanced medical treatments. Operating in the biopharmaceutical market, the company leverages its expertise in immunology to create therapies that intelligently target specific pathways within the immune system.

Read full description

The business model of RAPT Therapeutics revolves around research and development (R&D) of novel drug candidates, which are then advanced through clinical trials. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary drugs once they receive regulatory approval. RAPT Therapeutics also attracts investment opportunities, which help fund its ongoing R&D efforts and clinical trials.

Key clients include healthcare providers, research institutions, and pharmaceutical companies interested in innovative treatments for cancer and inflammatory diseases. The company aims to improve and empower countless lives by offering effective and targeted therapeutic solutions.

Source: Dealroom company data

At a glance

Founded
2013
Headquarters
San Francisco, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

Team profiled 38 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States92.5%
🇬🇧 United Kingdom4.5%
🇿🇼 Zimbabwe1.5%
🇫🇷 France1.5%
4 countries shown
Web traffic by country
8.9K monthly visits
across markets
🇺🇸 United States44.9%
🇨🇦 Canada22.5%
🇮🇳 India19.1%
🇯🇵 Japan13.5%
Top 4 markets shown

Patents

Estimated portfolio value
$28M

19 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about RAPT Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See RAPT Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.